Clinical Trial

A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC

Unknown Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated July 3, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study uses a prospective cohort design.Subjects are randomly divided into three groups (A, B, C) before surgery. Group A gets 3 cycles of sintilimab + chemo, Group B gets 2 cycles + 1 cycle, and Group C gets 1 cycle + 2 cycles. Non-squamous NSCLC subjects receive pemetrexed/albumin paclitaxel + platinum, while squamous NSCLC subjects get albumin paclitaxel + platinum.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT06485557
Lead Sponsor Tang-Du Hospital
Conditions Resectable Non-small Cell Lung Cancer
Enrollment 90 participants
Start Date 2024-08-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-08-01 (estimated)
Updated on ClinicalTrials.gov 2024-07-03